TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B
Brief Summary: This study will examine the safety, pharmacokinetics and efficacy of rIX-FP for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia B.


Options:
A: Arm Label: On-demand first; Type: OTHER; Interventions: Drug: activated prothrombin complex concentrate (FEIBA) | Arm Label: Prophylaxis first; Type: OTHER; Interventions: Drug: activated prothrombin complex concentrate (FEIBA) | Intervention Type: DRUG; Name: activated prothrombin complex concentrate (FEIBA); Assigned to Arm(s): On-demand first, Prophylaxis first
B: Arm Label: BAY94-9027 / Adynovi; Type: EXPERIMENTAL; Interventions: Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi), Biological: Rurioctocog alfa pegol (Adynovi) | Arm Label: Adynovi / BAY94-9027; Type: EXPERIMENTAL; Interventions: Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi), Biological: Rurioctocog alfa pegol (Adynovi) | Intervention Type: BIOLOGICAL; Name: Damoctocog-alfa-pegol (BAY94-9027, Jivi); Assigned to Arm(s): Adynovi / BAY94-9027, BAY94-9027 / Adynovi | Intervention Type: BIOLOGICAL; Name: Rurioctocog alfa pegol (Adynovi); Assigned to Arm(s): Adynovi / BAY94-9027, BAY94-9027 / Adynovi
C: Arm Label: Prophylaxis; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Arm Label: On-demand; Type: EXPERIMENTAL; Interventions: Biological: rIX-FP | Intervention Type: BIOLOGICAL; Name: rIX-FP; Assigned to Arm(s): On-demand, Prophylaxis
D: Arm Label: All participants; Type: EXPERIMENTAL; Interventions: Drug: BIIB031 (rFVIIIFc), Drug: FVIII (PK subgroup only) | Intervention Type: DRUG; Name: BIIB031 (rFVIIIFc); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: FVIII (PK subgroup only); Assigned to Arm(s): All participants

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study to Compare the Efficacy and Safety of a Novel 10% Ibuprofen Formulation Versus Placebo Alone Applied to the Knee in Patients With Painful Osteoarthritis of the Knee
Brief Summary: This is a phase 2a clinical trial performed to evaluate the efficacy of a topical treatment of ibuprofen compared to the use of a placebo topical treatment.

A multi-center, double-blinded, randomized placebo controlled study. Study length: 14 days Dosing twice daily (b.i.d.)


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac Sodium Gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac Sodium Gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: ketoprofen in Diractin® | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: celecoxib | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ketoprofen in Diractin®; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: Diclofenac topical sodium gel 1%; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 for Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Brief Summary: The purpose of this study is to evaluate the safety, tolerability and effectiveness of DS-5565 compared to placebo (inactive substance) and pregabalin in diabetic subjects with DPN.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin (Lyrica) | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Pregabalin (Lyrica); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: DS-5565 5mg nighttime; Type: EXPERIMENTAL; Interventions: Drug: DS-5565 tablet, Drug: placebo capsule | Arm Label: DS-5565 10 mg at bedtime; Type: EXPERIMENTAL; Interventions: Drug: DS-5565 tablet, Drug: placebo capsule | Arm Label: DS-5565 15 mg at bedtime; Type: EXPERIMENTAL; Interventions: Drug: DS-5565 tablet, Drug: placebo capsule | Arm Label: DS-5565 20 mg total per day; Type: EXPERIMENTAL; Interventions: Drug: DS-5565 tablet, Drug: placebo capsule | Arm Label: DS-5565 30 mg total per day; Type: EXPERIMENTAL; Interventions: Drug: DS-5565 tablet, Drug: placebo capsule | Arm Label: Pregabalin 300 mg total per day; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin capsule, Drug: Placebo tablet | Intervention Type: DRUG; Name: DS-5565 tablet; Assigned to Arm(s): DS-5565 10 mg at bedtime, DS-5565 15 mg at bedtime, DS-5565 20 mg total per day, DS-5565 30 mg total per day, DS-5565 5mg nighttime | Intervention Type: DRUG; Name: pregabalin capsule; Assigned to Arm(s): Pregabalin 300 mg total per day | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Pregabalin 300 mg total per day | Intervention Type: DRUG; Name: placebo capsule; Assigned to Arm(s): DS-5565 10 mg at bedtime, DS-5565 15 mg at bedtime, DS-5565 20 mg total per day, DS-5565 30 mg total per day, DS-5565 5mg nighttime
C: Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin
D: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Kaabong, Karamoja, Uganda
Brief Summary: The purpose of this study is to determine whether 14 days nutritional supplementation with Ready to use therapeutic Food (RUTF) or micronutrients alone to children having an infection will prevent malnutrition and reduce the frequency of morbidity.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Other: Nutritional Counselling and Education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation without Zinc | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Supplementation with Zinc | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation without Zinc; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Supplementation with Zinc; Assigned to Arm(s): C | Intervention Type: OTHER; Name: Nutritional Counselling and Education; Assigned to Arm(s): A
B: Arm Label: Ready to Use Therapeutic Food (RUTF); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Arm Label: Micronutrient Powder (MNP); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient Powder (MNP) | Arm Label: no supplement; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Ready to Use Therapeutic Food (RUTF); Assigned to Arm(s): Ready to Use Therapeutic Food (RUTF) | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient Powder (MNP); Assigned to Arm(s): Micronutrient Powder (MNP)
C: Arm Label: MNP+iron and test meal; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fortified maize porridge (MNP+iron) | Arm Label: MNP+iron+GOS and test meal; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fortified maize porridge (MNP+iron+GOS) | Intervention Type: DIETARY_SUPPLEMENT; Name: Fortified maize porridge (MNP+iron); Assigned to Arm(s): MNP+iron and test meal | Intervention Type: DIETARY_SUPPLEMENT; Name: Fortified maize porridge (MNP+iron+GOS); Assigned to Arm(s): MNP+iron+GOS and test meal
D: Arm Label: Experimental: Ready to Use Terapeutic Food (RUTF); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Supplement: Nutrition supplement with RUTF or MNP | Arm Label: Multi Micronutrient Powder (MNP); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Supplement: Nutrition supplement with RUTF or MNP | Arm Label: no supplement; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Supplement: Nutrition supplement with RUTF or MNP; Assigned to Arm(s): Experimental: Ready to Use Terapeutic Food (RUTF), Multi Micronutrient Powder (MNP)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Is the Placental Transfusion Volume Influenced by the Position of the New Born at Birth?
Brief Summary: To compare the evolution of the infant's weight before delayed cord clamping (2 minutes after birth) as an indirect measure of the volume of placental transfusion in a group of healthy and fullterm newborns, placed at the level of the introitus versus another group placed on the abdomen of the mother.


Options:
A: Arm Label: Early umbilical cord clamping (control); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Delayed umbilical cord clamping; Type: EXPERIMENTAL; Interventions: Procedure: Delayed umbilical cord clamping | Intervention Type: PROCEDURE; Name: Delayed umbilical cord clamping; Assigned to Arm(s): Delayed umbilical cord clamping
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Delayed Cord Clamping | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate Cord Clamping | Intervention Type: PROCEDURE; Name: Delayed Cord Clamping; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Immediate Cord Clamping; Assigned to Arm(s): B
C: Arm Label: Position at introitus level; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Position at introitus level | Arm Label: Position at Maternal Abdomen; Type: EXPERIMENTAL; Interventions: Procedure: position at Maternal Abdomen | Intervention Type: PROCEDURE; Name: Position at introitus level; Assigned to Arm(s): Position at introitus level | Intervention Type: PROCEDURE; Name: position at Maternal Abdomen; Assigned to Arm(s): Position at Maternal Abdomen
D: Arm Label: Early cord clamping (ECC); Type: OTHER; Interventions: Procedure: Early (≤30 seconds) cord clamping | Arm Label: Delayed cord clamping (DCC); Type: OTHER; Interventions: Procedure: Delayed (≤180 seconds) cord clamping | Intervention Type: PROCEDURE; Name: Early (≤30 seconds) cord clamping; Assigned to Arm(s): Early cord clamping (ECC) | Intervention Type: PROCEDURE; Name: Delayed (≤180 seconds) cord clamping; Assigned to Arm(s): Delayed cord clamping (DCC)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intradermal Route in Healthy BCG-vaccinated Adult Subjects
Brief Summary: This is a phase I trial to compare the safety and immunogenicity of candidate TB vaccine MVA85A administered by the aerosol inhaled route and the intradermal route in healthy BCG-vaccinated adult subjects.


Options:
A: Arm Label: Investigational Vaccine; Type: EXPERIMENTAL; Interventions: Biological: MVA85A/AERAS-485 | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Candida Skin Test Antigen | Intervention Type: BIOLOGICAL; Name: MVA85A/AERAS-485; Assigned to Arm(s): Investigational Vaccine | Intervention Type: BIOLOGICAL; Name: Candida Skin Test Antigen; Assigned to Arm(s): Control Group
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Intervention Type: BIOLOGICAL; Name: BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group A, Group C | Intervention Type: BIOLOGICAL; Name: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group B, Group D
C: Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): N/A
D: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Aerosol inhaled MVA85A | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Intradermal MVA85A | Intervention Type: BIOLOGICAL; Name: Aerosol inhaled MVA85A; Assigned to Arm(s): Group 1 | Intervention Type: BIOLOGICAL; Name: Intradermal MVA85A; Assigned to Arm(s): Group 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial Effect of Novel Intervention to Improve Stroke Symptom Recognition
Brief Summary: Despite the abundance of stroke education materials available, studies continue to reveal severe deficiencies in stroke literacy (knowledge of symptoms, urgent action, and prevention measures). Expensive mass media stroke education campaigns are not sustainable for this purpose, particularly in economically disadvantaged populations. Instead, the investigators propose to intervene in school classrooms with children aged 9 to 11 years, to teach the five cardinal stroke symptoms, the correct course of action when they occur, and to highlight the potential therapeutic benefit of early hospital arrival, with the intent that the children will then educate their parents. To help accomplish this, the investigators have developed a program called Hip Hop Stroke (HHS), which is comprised of rap songs and two animated musical cartoons that incorporate stroke knowledge.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Care Transitions Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care Transitions Intervention | Intervention Type: BEHAVIORAL; Name: Care Transitions Intervention; Assigned to Arm(s): Care Transitions Intervention
B: Arm Label: Hip Hop Stroke educational program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hip Hop Stroke educational program | Arm Label: Nutrition Education program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Nutrition Education program | Intervention Type: BEHAVIORAL; Name: Hip Hop Stroke educational program; Assigned to Arm(s): Hip Hop Stroke educational program | Intervention Type: BEHAVIORAL; Name: Nutrition Education program; Assigned to Arm(s): Nutrition Education program
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interactive educational program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual medical care | Intervention Type: BEHAVIORAL; Name: interactive educational program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: usual medical care; Assigned to Arm(s): 2
D: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily Compared to Fluticasone Propionate Delivered Twice Daily in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With High-strength Inhaled Corticosteroids or Mid-strength ICS/LABA Combination Therapy.
Brief Summary: A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy


Options:
A: Arm Label: FF/VI 200/25mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: GW685698/GW642444 | Arm Label: Fluticasone propionate 500mcg twice daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: CCI18781 | Intervention Type: DRUG; Name: GW685698/GW642444; Assigned to Arm(s): FF/VI 200/25mcg once daily | Intervention Type: DRUG; Name: CCI18781; Assigned to Arm(s): Fluticasone propionate 500mcg twice daily
B: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Arm Label: arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): arm 2 | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): arm 1
C: Arm Label: FF/VI; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate + vilanterol, Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Arm Label: ICS or ICS/LABA maintenance therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: inhaled corticosteroid with or without a long acting beta2-agonist | Intervention Type: DRUG; Name: fluticasone furoate + vilanterol; Assigned to Arm(s): FF/VI | Intervention Type: DRUG; Name: inhaled corticosteroid with or without a long acting beta2-agonist; Assigned to Arm(s): FF/VI, ICS or ICS/LABA maintenance therapy
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Vilanterol | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg, Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate 100mcg; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Arm 1, Arm 2, Arm 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate (FF/VI) Inhalation Powder Delivered Once Daily Compared to Fluticasone Propionate Delivered Twice Daily in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry Currently Treated With High-strength Inhaled Corticosteroids or Mid-strength ICS/LABA Combination Therapy.
Brief Summary: A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily in the treatment of asthma in adolescent and adult subjects of Asian ancestry currently treated with high-strength inhaled corticosteroids or mid-strength ICS/LABA combination therapy


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/formoterol fumarate 100/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/formoterol fumarate 100/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone propionate 100; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: FF/VI 200/25mcg once daily; Type: EXPERIMENTAL; Interventions: Drug: GW685698/GW642444 | Arm Label: Fluticasone propionate 500mcg twice daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: CCI18781 | Intervention Type: DRUG; Name: GW685698/GW642444; Assigned to Arm(s): FF/VI 200/25mcg once daily | Intervention Type: DRUG; Name: CCI18781; Assigned to Arm(s): Fluticasone propionate 500mcg twice daily
C: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo
D: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B